1. Home
  2. Planning Rare Disease Development in China

Planning Rare Disease Development in China

Live webinar · December 2, 2026

Planning rare disease development in China

Regulatory pathways and clinical trial considerations for international rare disease sponsors.

One hour, two perspectives: the China IND pathway from VCLS, rare disease trial delivery from Beijing Borrun, then a moderated panel and your questions answered live.

Event details
Wednesday, December 2, 2026
Live, then available on demand
9:00 AM ET · 2:00 PM GMT
60 minutes, live
9:00 AM New York6:00 AM Los Angeles2:00 PM London3:00 PM Paris10:00 PM Beijing
Online, in English
Free. 60 minutes with live Q&A. Joining link by email; recording and summary sent to every registrant.
Presented by VCLS (Voisin Consulting Life Sciences) and Beijing Borrun
Who it is for

Who is this webinar for?

This webinar is for regulatory, clinical and program leaders at biotech and pharmaceutical companies in Europe and the US who are deciding whether, and how, China fits into a rare disease development plan.

It is built around the questions sponsors ask when a program designed for FDA and EMA meets a third regulator. How does the National Medical Products Administration (NMPA) handle an IND for a rare condition, and how long does it take? What happens when a disease that is rare in Europe or the US is classified differently in China, or sits outside China’s national rare disease lists? Should China join the global MRCT or run its own study, and what does it take to open sites and find patients for a small-population study there?

The session is educational. Neither VCLS nor Beijing Borrun will present its services, and any claims about timelines, cost or regulatory advantage will be qualified and sourced.

Most useful if you are

  • Head of regulatory affairs, or the regulatory strategy lead on a rare disease program
  • Clinical development, clinical operations or medical lead planning a multinational study
  • CSO, CMO or program lead at an emerging biotech with a first global filing in view
  • Portfolio or business development lead assessing Asia-Pacific options for a rare disease asset
Agenda

What will the webinar cover?

Two presentations, a moderated panel and your questions, in one hour. Dr. Linsen Du of VCLS takes the regulatory pathway, Chika Yoshinaga, M.D. of Beijing Borrun takes trial delivery, and the two perspectives meet in the panel.

Times shown in US Eastern (ET) and GMT.

  1. 9:00 AM ET2:00 PM GMT · 5 min

    Welcome and introductions

    What the session covers, who is speaking, and how to put questions to the speakers through the Q&A panel.

    Anthony Murray, Head of Marketing & Communications, VCLS
  2. 9:05 AM ET2:05 PM GMT · 15 min

    Navigating China’s IND pathway

    A practical guide for global sponsors. Why China is worth considering for clinical development, and who does what at NMPA, CDE and NHC. The IND procedure and timeline, including the 30-day review track and the commitment that comes with it. Adapting an existing EU or US dossier for China, the planning steps that avoid common pitfalls, when CDE accepts overseas data in full, in part or not at all, and the incentives for rare disease therapies, including the 207-disease NHC catalogue and the options when a condition sits outside it.

    Dr. Linsen Du, General Manager, China, VCLS
  3. 9:20 AM ET2:20 PM GMT · 15 min

    Rare disease clinical trials in China

    Practical challenges, execution strategies and lessons from the field. How China’s rare disease framework links the disease catalogue, accelerated review, the national diagnosis and treatment network and reimbursement, and what the trial registration numbers say. Deciding between a global MRCT and a China-only study, the study start-up critical path from CTA submission to first patient, choosing sites for patient access rather than scale, and case studies on patient mapping, retention and patient management.

    Chika Yoshinaga, M.D., Head of International Business, Beijing Borrun
  4. 9:35 AM ET2:35 PM GMT · 10 min

    Panel discussion

    Where regulatory strategy meets trial execution. Three questions put to both speakers: joining a global MRCT without delaying the global timeline, planning submission and site activation together under the 30-day IND track, and the sponsor’s options when a condition is not in the NHC catalogue.

    Both speakers, moderated by Anthony Murray
  5. 9:45 AM ET2:45 PM GMT · 15 min

    Questions and answers

    Put your questions to Dr. Linsen Du and Chika Yoshinaga, M.D. through the Q&A panel, or send them in advance when you register.

    All speakers

Timings are indicative and may move as the program is finalized. The regulatory content is reviewed by the VCLS regulatory team before the session, and case studies are presented with sponsors anonymized.

Panel discussion

What will the panel discuss?

After the two presentations, the moderator puts three questions to both speakers. Each sits where regulatory strategy meets trial execution. Add your own on the registration form and it joins the list for the live Q&A.

  1. A sponsor has a global program built around FDA and EMA and wants China in the same MRCT. What has to change in the regulatory plan, and what in the operational plan, for China to join without delaying the global timeline?

    Dr. Linsen Du on dossier adaptation, the pre-IND meeting and aligning with CDE under ICH E17.

    Chika Yoshinaga, M.D. on putting the HGR filing, lead-site IRB and site contracts on one critical path.

  2. The 30-day IND track asks for the first patient consented within 12 weeks of approval, while site contracts alone can take 4 to 12 weeks. How should submission and site activation be planned together so neither stalls the other?

    Dr. Linsen Du on what the 12-week commitment means, and when the 30-day track is the wrong choice.

    Chika Yoshinaga, M.D. on parallel start-up, lead and backup sites, and what can be done before approval.

  3. When a condition is not among the 207 diseases in the NHC catalogue, what are the sponsor’s options? How does CDE’s case-by-case evaluation work in practice, and how do you find and enroll patients without a catalogue-driven diagnosis network?

    Dr. Linsen Du on the CARE program, the justification to CDE, and which incentives still apply.

    Chika Yoshinaga, M.D. on patient mapping through physician referrals, patient groups and registries.

Speakers

Who is speaking?

Dr. Linsen Du

General Manager, China
VCLS (Voisin Consulting Life Sciences)
Regulatory perspective

Linsen Du leads VCLS in China, where she established the firm’s practice in 2021. She supports biotech, pharmaceutical and MedTech companies with regulatory strategy, market access and clinical trial development in China and the wider APAC region, drawing on more than 15 years in regulatory science and medical affairs. Before VCLS she was Vice President, Regulatory and Medical Affairs at BravoVax in Wuhan, where she helped direct the development of rotavirus, pneumococcal conjugate and COVID-19 vaccines, and lead scientist at Covance’s central laboratory in Singapore. She has consulted for the Bill & Melinda Gates Foundation’s China Vaccine Program and holds a PhD in Biological Sciences from the National University of Singapore.

Chika Yoshinaga, M.D.

Head of International Business
Beijing Borrun Clinical Research
Clinical operations perspective

Chika Yoshinaga leads international business at Beijing Borrun, connecting global biotech sponsors with China’s clinical development ecosystem. Her background spans clinical medicine, life sciences venture capital, CRO strategy and cross-border drug development. She has invested in US and European biotech companies, held a strategic leadership role at IQVIA covering Japan and China, and founded a consulting firm focused on regulatory strategy, licensing and market entry. Since 2018 she has combined venture investment with CRO services to build the value of biotech assets through early clinical development in Asia.

Moderated by Anthony Murray, Head of Marketing & Communications, VCLS. Anthony opens the session, keeps time and puts your questions to the speakers.

Included

What do you receive when you register?

The agenda and joining details

GoTo Webinar emails your personal joining link when you register, then reminders a week before and on the day.

Live Q&A

Ask the speakers directly during the session, or send a question in advance using the form.

The recording

Posted on YouTube and on this page within a few working days. Every registrant gets the link, whether or not you attend live.

A written summary

The key points from each speaker and any resources mentioned, sent after the session.

Registration

Register for the live session

Registration is free. If you can’t join live, register anyway and we’ll send you the recording and the summary.

Questions about the webinar, or a topic you’d like the speakers to cover?

enquiries@voisinconsulting.com

Registration runs on GoTo Webinar. VCLS uses the details you provide to manage your registration and send the webinar materials, and shares the attendee list with Beijing Borrun for this event only. See the VCLS privacy policy.

How registration works
  1. Register on GoTo Webinar. Name, work email and company. Add a question for the speakers if you have one.
  2. Confirmation by email with your personal joining link and a calendar entry.
  3. Reminders a week before and an hour before the session. The recording and summary follow by email.
Register

Free. Joining needs a browser or the GoTo app, and no account. Attendees in mainland China may need a VPN to reach GoTo Webinar; if that applies to you, register anyway and the recording will reach you by email.

Organizers

About the organizers

VCLS (Voisin Consulting Life Sciences)

VCLS (Voisin Consulting Life Sciences) is a specialist life sciences product development partner helping biotech, pharmaceutical, and MedTech innovators advance complex products through regulated development and toward patient access. With expertise across regulatory strategy, clinical research, vigilance, real-world evidence, market access, and medical, scientific, and commercial communications, VCLS supports clients from early development planning through global submissions, market access, and lifecycle management. Our teams bring scientific depth, regulatory experience, and practical development insight to some of the most demanding areas of innovation, including orphan and rare diseases, advanced therapies, biologics, combination products, and medical devices.

Beijing Borrun Clinical Research

Beijing Borrun Clinical Research is a full-service contract research organization helping biopharmaceutical and medical device companies plan and deliver clinical development in China. Founded in 2011 and headquartered in Beijing, with teams in Shanghai, Chengdu, Wuhan, Shijiazhuang, Shenyang, Xi’an, Jinan and Guangzhou, Beijing Borrun has undertaken more than 700 clinical research projects for over 300 clients. Its strongest heritage is in central nervous system research, particularly psychiatry and neurology, and it also supports programs in rare diseases, oncology, ophthalmology, pediatrics, immunology and metabolic disease, respiratory and infectious disease, and cardiovascular disease. Services cover development strategy, China regulatory affairs, Phase I–IV clinical operations, project and site management, medical services, data management and biostatistics, quality assurance, pharmacovigilance, SMO and participant recruitment, and real-world evidence and post-approval research, delivered by more than 600 staff across 80 cities, with relationships spanning 400 hospitals, 600 clinical departments and 1,000 investigators.

Practical details

Frequently asked questions

Is the webinar free?

Yes. Registration is free and open to anyone working in or with biotech, pharmaceutical and MedTech companies.

Will the webinar be recorded?

Yes. The recording goes on YouTube and on this page within a few working days of the live session, and every registrant receives the link and the written summary by email, whether or not they attended.

What time is the webinar in my time zone?

The live session on Wednesday, December 2, 2026 starts at 9:00 AM Eastern, 8:00 AM Central, 7:00 AM Mountain and 6:00 AM Pacific in the US; 2:00 PM in London (GMT); 3:00 PM in Paris and Berlin (CET); and 10:00 PM in Beijing (CST). The event card at the top of this page shows the start in your own time zone. If 6:00 AM Pacific is too early, register anyway and watch the recording the same week.

How do I join the webinar?

The session runs on GoTo Webinar. When you register you receive a personal joining link by email, with reminders a week before and an hour before the start. You can join from a browser or the GoTo app without creating an account. Attendees in mainland China may need a VPN to reach GoTo Webinar; if so, register anyway and watch the recording afterward.

What language is the session in?

English. The slides, the presentations and the Q&A are all in English.

Is this a sales presentation?

No. The program was planned around what a sponsor needs to understand before committing to China, and neither VCLS nor Beijing Borrun will present a capabilities overview. Examples are anonymized and chosen for the lesson they carry.

Can I submit a question in advance?

Yes. There is a question field on the GoTo Webinar registration form, or email it to enquiries@voisinconsulting.com. The moderator will put as many questions as time allows to the speakers.

Who do I contact with a question about the event?

Email enquiries@voisinconsulting.com. For regulatory or clinical questions that go beyond the session, the same address reaches the VCLS team.

Reserve your place

Wednesday, December 2, 2026 · 9:00 AM ET / 2:00 PM GMT · 60 minutes · Online

Register Can’t make it live? Register for the recording.
Program details last updated November 11, 2026. Speaker names, titles and biographies are confirmed with each speaker before publication.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.